SLC5A2 and infection: We then review the current clinical evidence in KTRs, including glycemic control, graft function, safety (with an emphasis on infection risk), and the potential link between SGLT‐2 inhibitors and rejection, and discuss how SGLT‐2 inhibitors might complement existing immunosuppressive regimens.